CURRICULUM VITAE



NAME
Ippei Shimizu M.D., Ph.D. FESC, FAHA
Associate Professor
Department of Cardiovascular Biology and Medicine
Juntendo University Graduate School of Medicine, Tokyo, Japan

OFFICE ADDRESS
2-1-1 Hongo Bunkyoku Tokyo, Japan, Zipcode 113-8421
Phone: +81-3-5802-1054 Fax: +81-3-5689-0627
E-mail: ippeishimizu@yahoo.co.jp
Homepage: http://www.mol-aging.com/

PERSONAL INFORMATION
Date of birth: 26/4/1977
Gender: Male
Nationality: Japanese
Languages: Japanese and English

EDUCATION

2006-2010	Doctoral coarse, Chiba university graduate school of medicine (Chiba, Japan)
1996-2002	Chiba University faculty of medicine (Chiba, Japan)

POSTDOCTORAL EDUCATION

2012-2013(~June)	Boston University School of Medicine, Whitaker Cardiovascular Institute, Molecular Cardiology, postdoctoral fellow (Boston USA, Prof. Kenneth Walsh)
2010-2012	Chiba University Hospital Department of Cardiology, postdoctoral fellow

FACULTY ACADEMIC APPOINTMENTS

2021(April)- till present	Associate Professor, Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine
2014(April)-2021(March)	Associate Professor, Department of Cardiovascular Biology and Medicine Division of Molecular Aging and Cell Biology, Niigata University Graduate School of Medical and Dental Sciences, Japan
2013-2014	Research Instructor of Medicine, Boston University School of Medicine (Boston USA, Prof. Kenneth Walsh)

WORK EXPERIENCE

2021(April)- present	Associate Professor, Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine
2017-present	Member of AMED for Project for Elucidating and Controlling Mechanisms of Aging and Longevity from Japan Agency for Medical Research and Development
2016-2021(March)	Research chief of the ischemic heart disease and regenerative therapy group Research chief of the heart failure group
2014(April)-2021(March)	Associate Professor, Department of Cardiovascular Biology and Medicine Division of Molecular Aging and Cell Biology, Niigata University Graduate School of Medical and Dental Sciences, Japan
2013-2014	Boston University School of Medicine, Research Instructor of Medicine
2012-2013	Boston University School of Medicine, Whitaker Cardiovascular Institute, Molecular Cardiology, postdoctoral fellow
2010-2012	Chiba University Hospital Department of Cardiology, postdoctoral fellow
2004-2006	Sakakibara Heart Institute, Cardiovascular Internal Medicine, specialist trainee
2002-2004	National Center for Global Health and Medicine, foundation house officer

EDITORIAL BOARD MEMBERSHIP etc

1. Associate Editorial board member; ***Frontiers in Cardiovascular Medicine***
2. Editorial board member; ***J Mol Cell Cardiol***
3. Editorial board member; ***Scientific Reports***
4. International reviewer member; ***Diabetes and Metabolism Journal***
5. **Fellow;** European Society of Cardiology (FESC)
6. **Fellow;** American Heart Association (FAHA)
7. **Leader;** U45 International Society of Heart Research (ISHR) Japanese section (https://www.u45ishr.com/)

PUBLICATIONS (Representative)

1. Hsiao YT*, **Shimizu I*,****, Wakasugi T, Jiao S, Watanabe T, Yoshida Y, Ikegami R, Hayashi Y, Suda M, Katsuumi G, Nakao M, Ozawa T, Kashimura T, Ozaki K, Hanawa H, Minamino T**. Cardiac Mitofusin-1 is Reduced in Non-responding Patients with Idiopathic Dilated Cardiomyopathy. ***Co-first author,** **Co-corresponding author* ***Sci Rep.*** Mar24; 11(1):6722, 2021. *Co-first author, **Co-corresponding author
2. Yoshida Y*, **Shimizu I***, Hayashi Y, Ikegami R, Suda M, Katsuumi G, Wakasugi T, Nakao M, Nakagmi H, Morishita R, Minamino T. Peptide vaccine for semaphorin3E ameliorates systemic glucose intolerance in mice with dietary obesity. ***Sci Rep*** 2019 Mar7; 9(1)3858 ***Co-first author**
3. Ikegami R*, **Shimizu I***,**, Sato T*, Yoshida Y, Hayashi Y, Suda M, Katsuumi G, Li J, Wakasugi T, Minokoshi Y, Okamoto S, Hinoi E, Nielsen S, Jespersen N, Scheele C, Soga T, Minamino T**. Gamma-aminobutyric acid signaling in brown adipose tissue promotes systemic metabolic dysfunction in obesity. *Co-first author, **Co-corresponding author ***Cell Rep.*** 24(11):2827-2837 2018
4. Furuuchi R*, **Shimizu I***, Yoshida Y, Hayashi Y, Ikegami R, Suda M, Katsuumi G, Wakasugi T, Nakao M, Minamino T. Boysenberry polyphenol inhibits endothelial dysfunction and improves vascular health. ***PLOS One.*** 13(8):e0202051, 2018**. *Co-first author**
5. Katsuumi G*, **Shimizu I***, Yoshida Y, Minamino T. Vascular senescence in cardiovascular and metabolic diseases. ***Front Cardiovasc Med*** 05 March 2018 https://doi.org/10.3389/fcvm.2018.00018. ***Co-first author**
6. Ikegami R*, **Shimizu I***, Yoshida Y, Minamino T. Metabolomic analysis in heart failure. ***Circ J*** 2017 ;82(1):10-16 ***Co-first author**
7. Suda M*, **Shimizu I***, Yoshida Y, Hayashi Y, Ikegami R, Katsuumi G, Wakasugi T, Yoshida Y, Okuda S, Soga T, Minamino T. Inhibition of Dipeptidyl peptidase-4 ameliorates cardiac ischemia and systolic dysfunction by up-regulating the FGF-2/EGR-1 pathway. *Co-first author ***PLOS One*** 2017 Aug 3; 12(8), e0182422.
8. **Shimizu I***, Minamino T*. Physiological and pathological cardiac hypertrophy. ***J Mol Cell Cardiol.*** 2016 Jun 2;97:245-262 ***Co-corresponding author**
9. **Shimizu I**, Yoshida Y, Minamino T. ***Hypertens Res*** 2016 Feb 18, A role for circadian clock in metabolic disease.
10. **Shimizu I**, Yoshida Y, Minamino T. ***Diabetes.*** 2015 (Commentary) Dec;64(12):3984-6. Maintenance of subcutaneous fat homeostasis improves systemic metabolic dysfunction in obesity.
11. Yoshida Y*, **Shimizu I***, Katsuumi G*, Suda M, Hayashi Y, Minamino T. ***J Mol Cell Cardiol.*** 2015 June 85:183-198. p53-induced inflammation exacerbates cardiac dysfunction during pressure overload. ***Co-first author**
12. **Shimizu I**, Yoshida Y, Suda M, Minamino T. ***Cell Metab.*** 2014 Dec 2;20(6):967-977. DNA damage response and metabolic disease.
13. Kikuchi R, Nakamura K, Maclauchlan S, Ngo D, **Shimizu I**, Fuster J, Katanasaka Y, Yoshida S, Qiu Y, Yamaguchi T, Matsushita T, Murohara T, Gokce N, Bates D, Hamburg N, Walsh K. ***Nat Med.*** 2014 Dec;20(12):1464-71. An anti-angiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease.
14. **Shimizu I**, Tamar A, Kikuchi R, Shimizu A, Papanicolaou K, Maclauchlan S, Maruyama S, Walsh K. ***J Clin Invest.*** 2014; May;124(5):2099-112. Vascular rarefaction mediates whitening of brown fat in obesity.
15. **Shimizu I**, Yoshida Y, Moriya J, Nojima A, Uemura A, Kobayashi Y, Minamino T. ***Cell Metab.*** 2013 Oct1;18(4):491-504. Semaphorin3E-induced inflammation contributes to insulin resistance in dietary obesity. (Featured article)

16. **Shimizu I**, Walsh K. ***J Mol Cell Cardiol.*** 2013 Jun;59:176-8. Vascular remodeling mediated by Angptl2 produced from perivascular adipose tissue.
17. Naito AT, Sumida T, Nomura S, Liu ML, Higo T, Nakagawa A, Okada K, Sakai T, Hashimoto A, Hara Y, **Shimizu I**, Zhu W, Toko H, Katada A, Akazawa H, Oka T, Lee JK, Minamino T, Nagai T, Walsh K, Kikuchi A, Matsumoto M, Botto M, Shiojima I, Komuro I. ***Cell.*** 2012; 149: 1298-313. Complement C1q Activates Canonical Wnt Signaling and Promotes Aging-Related Phenotypes.
18. **Shimizu I**, Yoshida Y, Katsuno T, Tateno K, Okada S, Moriya J, Yokoyama M, Nojima A, Ito T, Zechner R, Komuro I, Kobayashi Y, Minamino T. ***Cell Metab.*** 2012; 15:51-64. p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. (Featured article)
19. **Shimizu I,** Minamino T, Toko H, Okada S, Ikeda H, Yasuda N, Tateno K, Moriya J, Yokoyama M, Nojima A, Koh G, Akazawa H, Shiojima I, Kahn C, Abel E, & Komuro I. ***J Clin Invest.*** 2010;120:1506-1514. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents.
20. Minamino T*, Orimo M*, **Shimizu I***, Kunieda T, Yokoyama M, Ito T, Nojima A, Nabetani A, Oike Y, Matsubara H, Ishikawa F, Komuro I. ***Nat Med.*** 2009; 15:1082-7. A crucial role for adipose tissue p53 in the regulation of insulin resistance. ***Co-first author**
21. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, Akazawa H, Tateno K, Kayama Y, Harada M, **Shimizu I**, Asahara T, Hamada H, Tomita S, Molkentin JD, Zou Y, Komuro I. ***Nature.*** 2007; 446:444-8. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload.